Resources

As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster highlights PATH’s four-phase approach to designing a dissolvable microarray patch (MAP) for vaginal delivery of rilpivirine. In addition, the poster discusses the ways by which the approach has helped to define design requirements for an effective and discreet method (i.e., applicator) for delivering the long-lasting rilpivirine MAP for HIV pre-exposure prophylaxis.

As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster presents results from a user-acceptability study of two microarray patches (MAPs) in South Africa. The MAPs under assessment were designed for the self-administration of antiretrovirals, such as rilpilvirine, and may someday offer a discreet and effective form of PrEP protection for women at risk of HIV.

Saving Lives Through Better Data provides quarterly updates on the BID Initiative's efforts to improve data collection, quality, and use. It includes updates on progress, partnerships, and specific activities.

GHS Bulletin provides updates on outbreaks of global importance, news on issues in global health security, and progress in PATH’s country activities in support of the US government’s Global Health Security Agenda.

In Zambia, the continued prevalence of congenital syphilis is a risk to newborns, and can cause premature birth, low birth weight, birth defects, and even newborn death. When pregnant women are tested for syphilis, however, service providers can treat the infection and prevent transmission to newborns. PATH is focusing advocacy efforts on the scale-up of a newly available rapid syphilis test, which offers a low-cost, easy-to-use screening option.